Literature DB >> 20524132

Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients.

Yosuke Sugimoto1, Hideki Mochizuki, Hideaki Okumichi, Masaya Takumida, Michiya Takamatsu, Seiichi Kawamata, Yoshiaki Kiuchi.   

Abstract

BACKGROUND: We aimed to investigate the effects of a single 1-mg injection of intravitreal bevacizumab on iris vessels in neovascular glaucoma (NVG) patients.
METHODS: Twenty-two surgically resected irises from glaucoma patients were obtained during trabeculectomy. Eight were from patients with NVG who received a 1-mg injection of intravitreal bevacizumab (IVB) before glaucoma surgery, eight were from patients with primary open-angle glaucoma (POAG), and six were from patients with NVG who were not administered IVB. The collected iris specimens were compared after immunohistochemical staining with anti-CD34 monoclonal antibodies and anti-VEGF monoclonal antibody, and the percentage of CD34-positive and VEGF-positive regions in the total area of the specimens from the three groups was compared.
RESULTS: The difference in the CD34-positive area between all groups was statistically significant (p = 0.0061, Kruskal-Wallis test). There was no significant difference in the CD34-positive area between the NVG with IVB group and the POAG group (p = 0.3017, Mann-Whitney U test with Bonferroni correction). The POAG group had significantly fewer CD34-positive regions than the NVG without IVB group (p = 0.0019, Mann-Whitney U test with Bonferroni correction). Many vessels remained in the iris stroma, and there was no significant difference in the CD34-positive area between the NVG with IVB and NVG without IVB groups (p = 0.0357, Mann-Whitney U test with Bonferroni correction). The ratio of the length of CD34 expression on the iris surface in the NVG without IVB group was significantly longer than that in the NVG with IVB group (p = 0.0002, Mann-Whitney U test). The difference in VEGF expression between all groups was statistically significant (p = 0.04, Kruskal-Wallis test). There was no significant difference between the NVG with IVB group and the NVG without IVB group (p = 0.7963 Mann-Whitney U test with Bonferroni correction). The frequency of hyphema and fibrin formation in the anterior chamber 1 day after surgery between the two NVG groups was not statistically significant.
CONCLUSION: A single intravitreal dose of IVB at 1 mg/0.04 ml to eyes with rubeotic glaucoma reduced the neovascularization in the human iris surface, but could not eliminate completely neovascularization in iris stroma. This finding implies that the prevention of hyphema and fibrin formation based on the slit-lamp examination can not be predicted, even if neovascularization in iris surface seems to be eliminated by a single dose of IVB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524132     DOI: 10.1007/s00417-010-1406-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

1.  Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.

Authors:  Jayter Silva Paula; Rodrigo Jorge; Rogério Alves Costa; Maria de Lourdes V Rodrigues; Ingrid U Scott
Journal:  Acta Ophthalmol Scand       Date:  2006-08

2.  Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model.

Authors:  Sophie J Bakri; J Douglas Cameron; Colin A McCannel; Jose S Pulido; Ronald J Marler
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

3.  Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema.

Authors:  John O Mason; Michael A Albert; Rachel Vail
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

4.  Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.

Authors:  Milko E Iliev; Diego Domig; Ute Wolf-Schnurrbursch; Sebastian Wolf; Gian-Marco Sarra
Journal:  Am J Ophthalmol       Date:  2006-08-02       Impact factor: 5.258

5.  Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients.

Authors:  Yoshiaki Kiuchi; Reiko Sugimoto; Kazuto Nakae; Yoshihiro Saito; Shigeo Ito
Journal:  Ophthalmologica       Date:  2006       Impact factor: 3.250

6.  In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A.

Authors:  Antonella N Witmer; Bart C van Blijswijk; Cornelis J F van Noorden; Gijs F J M Vrensen; Reinier O Schlingemann
Journal:  J Histochem Cytochem       Date:  2004-01       Impact factor: 2.479

7.  Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.

Authors:  Yoshiaki Saito; Tomomi Higashide; Hisashi Takeda; Shinji Ohkubo; Kazuhisa Sugiyama
Journal:  Acta Ophthalmol       Date:  2009-09-23       Impact factor: 3.761

8.  Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.

Authors:  Taku Wakabayashi; Yusuke Oshima; Hirokazu Sakaguchi; Yasushi Ikuno; Atsuya Miki; Fumi Gomi; Yasumasa Otori; Motohiro Kamei; Shunji Kusaka; Yasuo Tano
Journal:  Ophthalmology       Date:  2008-04-28       Impact factor: 12.079

9.  Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.

Authors:  Shahin Yazdani; Kamran Hendi; Mohammad Pakravan
Journal:  J Glaucoma       Date:  2007-08       Impact factor: 2.503

10.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.

Authors:  Swaantje Peters; Peter Heiduschka; Sylvie Julien; Focke Ziemssen; Heike Fietz; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Am J Ophthalmol       Date:  2007-04-23       Impact factor: 5.258

View more
  13 in total

1.  Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens.

Authors:  Noriko Yoshida; Toshio Hisatomi; Yasuhiro Ikeda; Ri-ichiro Kohno; Yusuke Murakami; Hiroyuki Imaki; Akifumi Ueno; Kimihiko Fujisawa; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-13       Impact factor: 3.117

Review 2.  Research progress on the role of connective tissue growth factor in fibrosis of diabetic retinopathy.

Authors:  Teng Ma; Li-Jie Dong; Xue-Li Du; Rui Niu; Bo-Jie Hu
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

3.  Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma.

Authors:  M I Canut; A Alvarez; J Nadal; R Abreu; J A Abreu; J S Pulido
Journal:  Clin Ophthalmol       Date:  2011-05-24

4.  Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes.

Authors:  Bojie Hu; Yan Zhang; Qing Zeng; Qian Han; Lijuan Zhang; Mian Liu; Xiaorong Li
Journal:  Int J Mol Sci       Date:  2014-01-22       Impact factor: 5.923

5.  Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis.

Authors:  Shunji Nakatake; Shigeo Yoshida; Shintaro Nakao; Ryoichi Arita; Miho Yasuda; Takeshi Kita; Hiroshi Enaida; Yuji Ohshima; Tatsuro Ishibashi
Journal:  BMC Ophthalmol       Date:  2014-04-26       Impact factor: 2.209

6.  Suppression of Human Tenon Fibroblast Cell Proliferation by Lentivirus-Mediated VEGF Small Hairpin RNA.

Authors:  Zhongqiu Li; Wen Hua; Xuedong Li; Wei Wang
Journal:  J Ophthalmol       Date:  2017-01-11       Impact factor: 1.909

7.  Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy.

Authors:  Jin-Woo Kwon; Donghyun Jee; Tae Yoon La
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 8.  Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.

Authors:  Vanessa Andrés-Guerrero; Lucía Perucho-González; Julián García-Feijoo; Laura Morales-Fernández; Federico Saenz-Francés; Rocío Herrero-Vanrell; Luis Pablo Júlvez; Vicente Polo Llorens; José María Martínez-de-la-Casa; Anastasios-Georgios Konstas
Journal:  Adv Ther       Date:  2016-12-20       Impact factor: 3.845

9.  Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma.

Authors:  Satoko Nakano; Takako Nakamuro; Katsuhiko Yokoyama; Kunihiro Kiyosaki; Toshiaki Kubota
Journal:  J Ophthalmol       Date:  2016-08-14       Impact factor: 1.909

10.  Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma.

Authors:  Jun Young Ha; Tae Hee Lee; Mi Sun Sung; Sang Woo Park
Journal:  Korean J Ophthalmol       Date:  2017-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.